Hepatitis C News

PHILADELPHIA — In this video, Paul Kwo, MD, professor of medicine and director of hepatology at Stanford University, discusses recent efforts to advance elimination of hepatitis C virus.

Despite achieving cure with direct-acting antivirals, patients with chronic hepatitis C virus-related decompensated cirrhosis remain at risk for progression of portal hypertension, further decompensation and hepatocellular carcinoma.

A hepatitis C elimination program in Georgia reduced the estimated annual incidence of new infections by 61% since its launch in April 2015, which may accelerate efforts to reach the global 2030 elimination goal.

A new study provides the first evidence that illicit fentanyl use may play a role in hepatitis C transmission among injection drug users, according to researchers.

Every year on July 28th, clinicians and researchers recognize World Hepatitis Day to bring awareness to one of the world’s deadliest but preventable viruses and continue efforts to meet the global goal of eliminating viral hepatitis by 2030

Remaining current on screening for hepatocellular carcinoma correlated with a “survival benefit” in older adults with hepatitis C virus-related cirrhosis who achieved viral cure but later developed HCC, according to researchers.

Treatment of chronic hepatitis C virus with direct-acting antivirals improved liver-related morbidity and survival, regardless of hepatocellular carcinoma, although patients aged older than 60 years should be monitored, a presenter noted.

Hepatitis C virus clearance rates in all states fell well short of national elimination goals, a study published in MMWR showed.

During Hepatitis Awareness Month, the CDC and allied public health organizations launched educational campaigns to raise awareness of viral hepatitis, deflate stigma around the infection and encourage early testing and vaccination.